CytomX Therapeutics Partner
CytomX Therapeutics is a clinical-stage biopharmaceutical company founded in 2008, focused on advancing cancer treatment through innovative therapies. Headquartered in the U.S., the company specializes in Probody® therapeutics, a proprietary technology that enhances the safety and effectiveness of cancer treatments by selectively activating therapies within the tumor microenvironment.
The Probody platform allows for the development of therapies that remain inactive in healthy tissues but activate specifically in tumors, aiming to minimize off-target toxicity. CytomX's pipeline includes several clinical-stage programs, such as CX-2029, a Probody-drug conjugate targeting CD71, and CX-904, a T-cell-engaging bispecific antibody targeting EGFR and CD3. The company has established strategic partnerships with major pharmaceutical firms like Bristol-Myers Squibb, Amgen, and AbbVie to support its mission of improving cancer care. CytomX is committed to diversity and inclusion within its workplace, fostering a collaborative environment dedicated to its goal of transforming cancer treatment.
